Contingency Management for Methamphetamine Abstinence and HIV Post-Exposure Prophylaxis in Men Who Have Sex With Men
Status:
Completed
Trial end date:
2010-12-01
Target enrollment:
Participant gender:
Summary
This study seeks to decrease methamphetamine use and concomitant high-risk sexual behaviors
among methamphetamine-using men who have sex with men (MSM) by combining a biomedical
intervention with a behavioral intervention. The behavioral intervention will consist of an
8-week course of contingency management (CM) through which participants will be reinforced
for testing negative for methamphetamine metabolites during periodic urine analyses. The
biomedical intervention involves a 28-day course of an antiretroviral drug (Truvada) to be
administered after an unanticipated HIV risk exposure (i.e., engaging in either receptive or
insertive anal sex without a condom with someone who is HIV-positive or of unknown status).
In combining these two interventions, this study seeks to evaluate the combined
intervention's effects on sexual risk behaviors and methamphetamine use.
Phase:
Phase 2
Details
Lead Sponsor:
Friends Research Institute, Inc.
Collaborator:
University of California, Los Angeles
Treatments:
Emtricitabine Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination Methamphetamine Tenofovir